Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

Abstract Randomized controlled trials (RCTs) are the gold standard to establish the benefit-risk ratio of novel drugs. However, the evaluation of mature results often takes many years. We hypothesized that the addition of Bayesian inference methods at interim analysis time points might accelerate an...

Full description

Bibliographic Details
Main Authors: Niek G. van der Maas, Jurjen Versluis, Kazem Nasserinejad, Joost van Rosmalen, Thomas Pabst, Johan Maertens, Dimitri Breems, Markus Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Löwenberg, Gerwin Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen
Format: Article
Language:English
Published: Nature Publishing Group 2024-03-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-024-01037-3

Internet

https://doi.org/10.1038/s41408-024-01037-3

Similar Items